keyword
MENU ▼
Read by QxMD icon Read
search

5- fluorouracil

keyword
https://www.readbyqxmd.com/read/29785331/nodular-basal-cell-carcinoma-of-the-face-successfully-treated-with-ingenol-mebutate-0-015-gel
#1
Silvia S Iannazzone, Vito Ingordo
Surgical excision is the first-choice treatment for basal cell carcinoma (BCC). Other treatments with topical agents such as 5-fluorouracil or imiquimod have also been suggested for use in superficial BCC (sBCC). Ingenol mebutate (IM) is a novel agent employed in the treatment of superficial actinic keratoses. The drug has been also successfully used in the treatment of sBCC. A case of large nodular BCC (nBCC) of the face in a 100-year-old inoperable woman is described. IM 0.015% gel was applied once daily for three consecutive days...
April 2018: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/29782360/a-phase-ii-study-of-celecoxib-with-irinotecan-5-fluorouracil-and-leucovorin-in-patients-with-previously-untreated-advanced-or-metastatic-colorectal-cancer
#2
Emerson Y Chen, Charles D Blanke, Daniel G Haller, Al B Benson, Tomislav Dragovich, Heinz-Josef Lenz, Carlos Robles, Hong Li, Motomi Mori, Nora Mattek, Rachel E Sanborn, Charles D Lopez
OBJECTIVE: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Cyclooxygenase-2 (COX-2) overexpression is associated with increased tumor invasiveness and proliferation in CRC, and COX-2 inhibition has demonstrated chemopreventive activity. This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC. PATIENTS AND METHODS: Forty-seven patients enrolled in this single-arm phase II study received celecoxib at 400 mg orally twice daily in combination with weekly irinotecan (125 mg/m), 5-fluorouracil (500 mg/m), and leucovorin (20 mg/m) for 4 weeks every 6 weeks...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29781107/pristimerin-targeting-nf-%C3%AE%C2%BAb-pathway-inhibits-proliferation-migration-and-invasion-in-esophageal-squamous-cell-carcinoma-cells
#3
Yuanqing Tu, Fuxing Tan, Jingfeng Zhou, Jingxuan Pan
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer-related death with poor prognosis in China. Identifying novel targeted therapies in ESCC is urgently needed. The aberrant activation of NF-κB signalling pathway is critical for prognosis and recurrence of ESCC, which make it a potential target in the treatment of ESCC. Here, we found that pristimerin inhibited ESCC cell proliferation, migration, invasion, induced cell apoptosis, and eliminated cancer stem-like cells (CSCs). It also showed a synergistic effect on ESCC when combined with 5-fluorouracil (5-FU)...
May 20, 2018: Cell Biochemistry and Function
https://www.readbyqxmd.com/read/29778788/maintaining-dose-intensity-of-adjuvant-chemotherapy-in-older-patients-with-breast-cancer
#4
Rahul Ladwa, Timothy Kalas, Shivanshan Pathmanathan, Natasha Woodward, David Wyld, Jasotha Sanmugarajah
INTRODUCTION: Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain the optimal RDI for standard chemotherapy regimens. The present study investigated the RDI of newer adjuvant chemotherapy regimens in this demographic. PATIENTS AND METHODS: We retrospectively analyzed the data from 281 patients aged ≥ 65 years with a diagnosis of ESBC who had received adjuvant chemotherapy across 3 sites in Queensland, Australia from 2010 to 2015...
April 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29777330/down-regulating-il-6-gp130-targets-improved-the-anti-tumor-effects-of-5-fluorouracil-in-colon-cancer
#5
Sanhong Li, Jilai Tian, Hongming Zhang, Shoubing Zhou, Xiyong Wang, Lei Zhang, Jiapeng Yang, Zhigang Zhang, Zhenling Ji
Recent studies have confirmed that IL-6/GP130 targets are closely associated with tumor growth, metastasis and drug resistance. 5-Fluorouracil (5-FU) is the most common chemotherapeutic agent for colon cancer but is limited due to chemoresistance and high cytotoxicity. Bazedoxifene (BZA), a third-generation selective estrogen receptor modulator, was discovered by multiple ligand simultaneous docking and drug repositioning approaches to have a novel function as an IL-6/GP130 target inhibitor. Thus, we speculated that in colon cancer, the anti-tumor efficacy of 5-FU might be increased in combination with IL-6/GP130 inhibitors...
May 18, 2018: Apoptosis: An International Journal on Programmed Cell Death
https://www.readbyqxmd.com/read/29776344/risk-factors-for-esophageal-fistula-in-thoracic-esophageal-squamous-cell-carcinoma-invading-adjacent-organs-treated-with-definitive-chemoradiotherapy-a-monocentric-case-control-study
#6
Takeshi Kawakami, Takahiro Tsushima, Katsuhiro Omae, Hirofumi Ogawa, Hiromichi Shirasu, Yosuke Kito, Yukio Yoshida, Satoshi Hamauchi, Akiko Todaka, Nozomu Machida, Tomoya Yokota, Kentaro Yamazaki, Akira Fukutomi, Yusuke Onozawa, Hirofumi Yasui
BACKGROUND: Standard treatment for unresectable esophageal squamous cell carcinoma (ESCC) without distant metastasis is definitive chemoradiotherapy (dCRT), in which the incidence of esophageal fistula (EF) is reported to be 10-12%. An ad hoc analysis of JCOG0303, a phase II/III trial of dCRT for patients with unresectable ESCC (including non-T4b), suggested that esophageal stenosis is a risk factor for EF. However, risk factors for EF in patients limited to T4b ESCC treated with dCRT have yet to be clarified...
May 18, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29774120/carboplatin-in-combination-with-weekly-paclitaxel-as-first-line-therapy-in-patients-with-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-unfit-to-extreme-schedule
#7
Adeline Pêtre, Cécile Dalban, Andy Karabajakian, Eve-Marie Neidhardt, Pierre Eric Roux, Marc Poupart, Sophie Deneuve, Philippe Zrounba, Jérome Fayette
The standard first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma combines Cisplatin, 5 Fluorouracil and Cetuximab, but many patients aren't eligible. We retrospectively evaluated the efficacy and the tolerability of Carboplatin and Paclitaxel in this indication, mostly in patients unfit to Cisplatin. Paclitaxel (80mg/m2) was administered at day 1, 8 and 15 and Carboplatin area under the curve 5 at day 1, repeated every 28 days, for 6 cycles. Carboplatin could be administered at area under the curve 2 at day 1, 8 and 15...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29772519/p53-and-p-glycoprotein-influence-chemoresistance-in-hepatocellular-carcinoma
#8
ShengLei Li, Ming Gao, ZongMing Li, LiJie Song, XianZheng Gao, Jing Han, Feng Wang, YongFang Chen, WenCai Li, JianPing Yang
Chemoresistance is a critical obstacle to the treatment of hepatocellular carcinoma (HCC). The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). p53 plays a role in cell growth; therefore, resistance mechanisms involve chemotherapy-induced apoptosis and p53 mutation and inactivation. P-gp is an energy-dependent drug efflux pump regulated by p53. Its role in drug resistance has provided new insights into the mechanisms underlying the involvement of p53 and P-gp in chemoresistance and may alter our traditional understanding of p53 and P-gp function...
June 1, 2018: Frontiers in Bioscience (Elite Edition)
https://www.readbyqxmd.com/read/29771440/mir-519d-reduces-the-5-fluorouracil-resistance-in-colorectal-cancer-cells-by-down-regulating-the-expression-of-ccnd1
#9
R Huang, J-Y Lin, Y-J Chi
OBJECTIVE: To investigate the effects of miR-519d on the 5-fluorouracil resistance in colorectal cancer cells and to explore the mechanism. MATERIALS AND METHODS: Colorectal cancer cells HCT116 and SW480 were transfected with miR519d-mimic or siCCND1 by transient transfection. The sensitivity of cells to 5-Fu was assayed by MTT assay. Dual luciferase assay was used to examine the effect of CCND1 on the sensitivity of cells to 5-Fu mediated by miR-519d. RESULTS: MiR-519d was overexpressed in colorectal cancer cells after transient transfection with miR-519d mimics...
May 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29771107/design-and-synthesis-of-a-biocompatible-1d-coordination-polymer-as-anti-breast-cancer-drug-carrier-5-fu-in-vitro-and-in-vivo-studies
#10
Mahsa Rezaei, Alireza Abbasi, Rassoul Dinarvand, Mahmood Jeddi-Tehrani, Jan Janczak
Designable coordination polymers with suitable chemical diversities and biocompatible structures have been proposed as a promising class of vehicles for drug delivery systems. Here, we hydrothermally synthesized a novel one-dimensional (1D) coordination polymer, [Zn(H2 O)6 K2 (H2 BTC)2 (H2 O)4 ](H2 BTC)2 ·2H2 O, where H3 BTC = benzene-1,3,5-tricarboxylic acid (trimesic acid), cp.1. As the hydrogen bonds stabilized 1D chains in three dimensions, the cp.1 could be a good candidate for delivering small-molecule chemotherapeutics such as 5-fluorouracil (5-Fu)...
May 17, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29769267/functional-characterization-of-21-allelic-variants-of-dihydropyrimidine-dehydrogenase-identified-in-1-070-japanese-individuals
#11
Eiji Hishinuma, Yoko Narita, Sakae Saito, Masamitsu Maekawa, Fumika Akai, Yuya Nakanishi, Jun Yasuda, Masao Nagasaki, Masayuki Yamamoto, Hiroaki Yamaguchi, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka
Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2), encoded by the DPYD gene, is the rate-limiting enzyme in the degradation pathway of endogenous pyrimidine and fluoropyrimidine drugs such as 5-fluorouracil (5-FU). DPD catalyzes the reduction of uracil, thymine, and 5-FU. In Caucasians, DPYD mutations, including DPYD*2A, DPYD*13, c.2846A>T, and 1129-5923C>G/hapB3, are known to contribute to interindividual variations in the toxicity of 5-FU. However, none of these DPYD polymorphisms have been identified in the Asian population...
May 16, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29768350/docetaxel-oxaliplatin-5fu-and-trastuzumab-as-first-line-therapy-in-patients-with-human-epidermal-receptor-2-positive-advanced-gastric-or-gastroesophageal-junction-cancer-preliminary-results-of-a-phase-ii-study
#12
Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion 5-fluorouracil mg/m days 1-5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29768280/phase-i-ii-trial-of-chemotherapy-with-docetaxel-cisplatin-and-s-1-for-unresectable-advanced-squamous-cell-carcinoma-of-the-esophagus
#13
Toshiyasu Ojima, Masaki Nakamura, Mikihito Nakamori, Masahiro Katsuda, Keiji Hayata, Shimpei Maruoka, Toshio Shimokawa, Hiroki Yamaue
Our previous trial with a docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen showed high response rates in metastatic squamous cell carcinoma of the esophagus (SCCE). The observed increased toxicity of the DCF regimen, however, was clinically harmful. S-1, an oral anticancer drug, has been approved as a combination therapy for SCCE, and alternate-day regimen with S-1 has shown lower levels of toxicity. This prospective single-center phase I/II trial examines the efficacy and toxicity of a combination of docetaxel, cisplatin, and an alternate-day regimen of S-1 (modified DCS) for patients with metastatic SCCE...
May 16, 2018: Oncology
https://www.readbyqxmd.com/read/29767264/elemental-diet-inhibits-pro%C3%A2-inflammatory-cytokine-production-in-keratinocytes-through-the-suppression-of-nf%C3%A2-%C3%AE%C2%BAb-activation
#14
Koji Harada, Tarannum Ferdous, Yoichi Mizukami, Katsuaki Mishima
An elemental diet (ED) has been reported to reduce oral mucositis and dermatitis induced by chemotherapy. However, its molecular mechanism of action as an anti‑inflammatory agent is still unknown. The aim of the present study was to clarify whether ED confers its anti‑inflammatory action via reduction of pro‑inflammatory cytokine production in keratinocytes in vivo and in vitro. We evaluated the efficacy of ED in the treatment of 5‑fluorouracil (5‑FU)‑induced dermatitis of nude mice, and examined the expression of pro‑inflammatory cytokines such as tumor necrosis factor‑α (TNF‑α), interleukin (IL)‑1β and IL‑6 using immunohistochemistry...
May 16, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29767247/comparison-of-the-synergistic-anticancer-activity-of-alpcs4-photodynamic-therapy-in-combination-with-different-low%C3%A2-dose-chemotherapeutic-agents-on-gastric-cancer-cells
#15
Jing Xin, Senhao Wang, Luwei Zhang, Bo Xin, Yulu He, Jing Wang, Sijia Wang, Lijian Shen, Zhenxi Zhang, Cuiping Yao
Limited cellular delivery and internalization efficiency of Al(III) phthalocyanine chloride tetrasulfonic acid (AlPcS4) induce poor penetration ability in cells and a slight photodynamic therapy (PDT) effect on gastric cancer. The combination treatment of AlPcS4/PDT with low‑dose chemotherapeutic agents may provide a promising treatment strategy to increase the weak delivery efficiency of AlPcS4, reducing the dose of chemical agents without reducing efficacy, and improving apoptosis‑inducing abilities, thereby increasing the antitumor effects and decreasing the noxious side effects on gastric cancer...
May 16, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29764506/cardiotoxicity-of-5-fluorouracil-and-capecitabine-in-chinese-patients-a-prospective-study
#16
Jianjun Peng, Chao Dong, Chang Wang, Weihua Li, Hao Yu, Min Zhang, Qun Zhao, Bo Zhu, Jun Zhang, Wenliang Li, Fenghua Wang, Qiong Wu, Wenhao Zhou, Ying Yuan, Meng Qiu, Gong Chen
BACKGROUND: 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date. In the present study, we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5-FU- and capecitabine-associated cardiotoxicity in cancer patients recruited from multiple centers in China...
May 11, 2018: Cancer communications
https://www.readbyqxmd.com/read/29764487/effect-of-induction-chemotherapy-with-cisplatin-fluorouracil-with-or-without-taxane-on-locoregionally-advanced-nasopharyngeal-carcinoma-a-retrospective-propensity-score-matched-analysis
#17
Guo-Ying Liu, Xing Lv, Yi-Shan Wu, Min-Jie Mao, Yan-Fang Ye, Ya-Hui Yu, Hu Liang, Jing Yang, Liang-Ru Ke, Wen-Ze Qiu, Xin-Jun Huang, Wang-Zhong Li, Xiang Guo, Yan-Qun Xiang, Wei-Xiong Xia
BACKGROUND: Available data in the literature comparing different induction chemotherapy (IC) regimens on locoregionally advanced nasopharyngeal carcinoma (NPC) are scarce. The purpose of the present study was to evaluate the outcomes of locoregionally advanced NPC patients who were treated with taxane, cisplatin and 5-fluorouracil (TPF) or cisplatin and 5-fluorouracil (PF) as IC followed by concurrent chemoradiotherapy (CCRT). METHODS: In total, 1879 patients with locoregionally advanced NPC treated with IC and CCRT from a prospectively maintained database were included in the present observational study...
May 10, 2018: Cancer communications
https://www.readbyqxmd.com/read/29762717/durable-complete-responses-in-some-recurrent-high-grade-glioma-patients-treated-with-toca-511-toca-fc
#18
Timothy F Cloughesy, Joseph Landolfi, Michael A Vogelbaum, Derek Ostertag, James B Elder, Stephen Bloomfield, Bob Carter, Clark C Chen, Steven N Kalkanis, Santosh Kesari, Albert Lai, Ian Y Lee, Linda M Liau, Tom Mikkelsen, Phioanh Nghiemphu, David Piccioni, William Accomando, Oscar R Diago, Daniel J Hogan, Dawn Gammon, Noriyuki Kasahara, Thian Kheoh, Douglas J Jolly, Harry E Gruber, Asha Das, Tobias Walbert
Background: Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of anti-tumor immunity. Recurrent high grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months...
May 12, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29762254/influence-of-regulatory-nlrc5-variants-on-colorectal-cancer-survival-and-5-fluorouracil-based-chemotherapy
#19
Calogerina Catalano, Miguel I da Silva Filho, Katerina Jiraskova, Veronika Vymetalkova, Miroslav Levy, Vaclav Liska, Ondrej Vycital, Alessio Naccarati, Ludmila Vodickova, Kari Hemminki, Pavel Vodicka, Alexander N R Weber, Asta Försti
BACKGROUND: NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival. OBJECTIVE: We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients. PATIENTS AND METHODS: We carried out a case-only study in a Czech population of 589 cases; 232 received 5-FU-based therapy...
May 14, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29762143/mucositis-and-cardiotoxicity-due-to-5-fluorouracil
#20
Eric Phillips, Alexandra France, George Thatvihane, Ukwuoma Nnaemeka, Samana Zaidi
No abstract text is available yet for this article.
March 23, 2018: American Journal of Therapeutics
keyword
keyword
27813
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"